Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158363 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL436024 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL2288397 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29792115 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29362301 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL21192401 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL5967470 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29401280 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31614333 | 0.94 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357757-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | PETROV, DIMITAR (CH) | 2023-11-09 | — | — | US | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4232578-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH Zurich (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-4106820-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | Elucida Oncology, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093794-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022084486-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH ZURICH (CH) | 2022-04-28 | — | — | WO | disclosed |